60509-40-2 Usage
Description
CHEMBRDG-BB 4022325 is a chemical compound with the formula C23H19FN4O3, characterized as a potent and selective inhibitor of both immunoproteasome and constitutive proteasome. CHEMBRDG-BB 4022325 has garnered attention for its potential therapeutic applications in managing autoimmune and inflammatory diseases, as well as in cancer therapy. Its efficacy in inhibiting tumor cell proliferation and modulating immune responses has been demonstrated in preclinical studies, although further research is necessary to elucidate its complete mechanism of action and explore its full therapeutic potential.
Uses
Used in Pharmaceutical Industry:
CHEMBRDG-BB 4022325 is used as a therapeutic agent for the treatment of autoimmune and inflammatory diseases due to its ability to modulate immune responses and potentially alleviate disease symptoms.
Used in Oncology:
CHEMBRDG-BB 4022325 is used as an anticancer agent for its demonstrated capacity to inhibit the proliferation of tumor cells, offering a potential new avenue for cancer therapy.
Used in Drug Development Research:
CHEMBRDG-BB 4022325 serves as a valuable compound in preclinical studies, aiding researchers in understanding the mechanisms of immunoproteasome and constitutive proteasome inhibition, which could lead to the development of novel treatments for a range of diseases.
Check Digit Verification of cas no
The CAS Registry Mumber 60509-40-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,0,5,0 and 9 respectively; the second part has 2 digits, 4 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 60509-40:
(7*6)+(6*0)+(5*5)+(4*0)+(3*9)+(2*4)+(1*0)=102
102 % 10 = 2
So 60509-40-2 is a valid CAS Registry Number.
InChI:InChI=1/C11H16BrN/c1-2-3-8-13-9-10-4-6-11(12)7-5-10/h4-7,13H,2-3,8-9H2,1H3
60509-40-2Relevant articles and documents
LINCOMYCIN DERIVATIVES AND ANTIBACTERIAL AGENTS CONTAINING THE SAME AS THE ACTIVE INGREDIENT
-
Page/Page column 39, (2010/03/02)
An objective of the present invention is to provide compounds of formula (1) or their pharmacologically acceptable salts or solvates wherein A represents aryl; R1 represents N-optionally substituted C1-6 alkyl-N-optionally substituted C1-6 alkylamino-C1-6 alkyl; R2 represents a hydrogen atom or optionally substituted C1-6 alkyl; R3 represents optionally substituted C1-6alkyl or C3-6 cycloalkyl-C1-4 alkyl; m is 1 to 3; n is 0; and p is 0 to 2. The compounds are novel lincomycin derivatives that have a potent activity against resistant Streptococcus pneumoniae, which have recently posed problems, in the treatment of infectious diseases. Further, the compounds are usable as antimicrobial agents and are useful for preventing or treating bacterial infectious diseases.
